Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O’Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O’Shaughnessy, Joyce, Gallagher, Clair, O’Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O’Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O’Donovan, Norma, Crown, John
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180577/
https://ncbi.nlm.nih.gov/pubmed/30305055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4852-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars